Mosaic Immunoengineering Inc
Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on advancing and commercialization of immunotherapies for the treatment of cancer. It engages in pursuing new product candidates and platforms to build a new pipeline based on immunotherapies. Mosaic ImmunoEngineering, Inc. was founded in 2020 and is based in Huntington Beach, California.
Mosaic Immunoengineering Inc (CPMV) - Net Assets
Latest net assets as of September 2025: $-7.31 Million USD
Based on the latest financial reports, Mosaic Immunoengineering Inc (CPMV) has net assets worth $-7.31 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($55.30K) and total liabilities ($7.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-7.31 Million |
| % of Total Assets | -13213.65% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 55.11 |
Mosaic Immunoengineering Inc - Net Assets Trend (2016–2024)
This chart illustrates how Mosaic Immunoengineering Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mosaic Immunoengineering Inc (2016–2024)
The table below shows the annual net assets of Mosaic Immunoengineering Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-6.79 Million | -15.62% |
| 2023-12-31 | $-5.87 Million | -20.19% |
| 2022-12-31 | $-4.88 Million | -74.52% |
| 2021-12-31 | $-2.80 Million | -562.42% |
| 2020-12-31 | $-422.54K | -166.43% |
| 2019-12-31 | $636.02K | -62.51% |
| 2018-12-31 | $1.70 Million | -32.00% |
| 2017-12-31 | $2.50 Million | -32.65% |
| 2016-12-31 | $3.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mosaic Immunoengineering Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5027979200.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $2.05 Million | % |
| Total Equity | $-6.79 Million | 100.00% |
Mosaic Immunoengineering Inc Competitors by Market Cap
The table below lists competitors of Mosaic Immunoengineering Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FendX Technologies Inc.
PINK:FDXTF
|
$533.08K |
|
Reliant Holdings Inc
OTCQB:RELT
|
$533.21K |
|
Dongbu HiTek Co. Ltd.
KQ:000990
|
$533.33K |
|
Imperial Pacific Ltd
AU:IPC
|
$533.56K |
|
BUZZI UNICEM
BE:UCM
|
$532.57K |
|
Busan Industrial Co. Ltd.
KQ:011390
|
$532.32K |
|
Libental
TA:LBTL
|
$532.14K |
|
Lingo Media Corporation
PINK:LMDCF
|
$531.94K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mosaic Immunoengineering Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -5,871,058 to -6,788,174, a change of -917,116.
- Net loss of 921,983 reduced equity.
- Other factors increased equity by 4,867.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-921.98K | -13.58% |
| Other Changes | $4.87K | +0.07% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Mosaic Immunoengineering Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $4.61 | $0.65 | x |
| 2017-12-31 | $3.11 | $0.65 | x |
| 2018-12-31 | $2.11 | $0.65 | x |
| 2019-12-31 | $0.79 | $0.65 | x |
| 2020-12-31 | $-0.52 | $0.65 | x |
| 2021-12-31 | $-0.39 | $0.65 | x |
| 2022-12-31 | $-0.67 | $0.65 | x |
| 2023-12-31 | $-0.81 | $0.65 | x |
| 2024-12-31 | $-0.94 | $0.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mosaic Immunoengineering Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-32.94%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -1.22% | 0.00% | 0.00x | 1.02x | $-415.81K |
| 2017 | -48.47% | 0.00% | 0.00x | 1.03x | $-1.46 Million |
| 2018 | -47.06% | 0.00% | 0.00x | 1.13x | $-968.12K |
| 2019 | -166.74% | 0.00% | 0.00x | 1.29x | $-1.12 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.40 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.89 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-421.13K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-243.17K |
Industry Comparison
This section compares Mosaic Immunoengineering Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mosaic Immunoengineering Inc (CPMV) | $-7.31 Million | -1.22% | N/A | $532.92K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |